GSK: conclusive phase III trial for linerixibat

(CercleFinance.com) - GSK announces that a Phase III clinical trial has met its primary endpoint, showing that linerixibat significantly reduced itching associated with primary biliary cholangitis (PBC) compared with placebo over a 24-week period.


The study enrolled patients with moderate to severe itching, receiving guideline treatments or untreated.

Preliminary safety results are consistent with previous studies.

Linerixibat could become the world's first treatment developed specifically for PBC-related itching, addressing an unmet need, GSK said.

PBC, a rare disease primarily affecting women, causes persistent itching impacting quality of life and currently has no curative treatment.

Full results will be presented at a future scientific congress.


Copyright (c) 2024 CercleFinance.com. All rights reserved.